What Not to Say When Someone is Venting

  • March 29, 2022
  • contact@ketaminemedia.com

We all vent from time to time. We get stressed out, feel anxious, or maybe succumb to a hint of depression in our daily lives, and the influx of emotion becomes a whirling dervish of pain. To relieve that pain – and perhaps anger or frustration – we often turn to that time-honored practice of…

3,4-methylenedioxymethamphetamine (MDMA), also known as “molly,” has been found to be highly effective for the treatment of post-traumatic stress disorder (PTSD) when used with conventional therapy and psychotherapy methods. The phase 3 clinical trial results were presented Tuesday at the American Chemical Society meeting in San Diego, California. A review of data from the phase…

Dr. Bronner’s, a well-known liquid soap company that has evolved into a household name, is making waves in the industry. A new campaign is coming that promotes the benefits of psychedelics. The brand is famous for its bottles with tiny-font labels that line the shelves of supermarkets across the country. Often, it lists the ingredients…

The Fed Just Became A Little More Psychedelic.

  • March 17, 2022
  • contact@ketaminemedia.com

By David Connell, Ketamine NewsThursday, March 17, 2022 John Hopkins University has always been a leader in the research and development of novel new psychotherapy treatments. Now their prestigious Center of Psychedelics and Consciousness Research will be at the forefront of research into the possible use of the classical psychedelic compound Psilocybin to treat depression….

By David Connell, Ketamine NewsThursday, January 27, 2022 A pair of state legislators in Oklahoma recently filed a bill that, if enacted, would decriminalize adult use and possession of psilocybin and other psychedelics while also encouraging and regulating research into their possible therapeutic benefits. Reps. Daniel Pae (R) and Logan Phillips (R) introduced the legislation…

“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explained primary trial investigator Dr. David J. Hellerstein. Compass Pathways eagerly awaited trial results are out, and the findings are impressive. With their COMP360 psilocybin therapy drug, Compass Pathways’ trial has shown that psilocybin-based therapy rapidly reduced the severity of…

Washington State Helps Pioneer Psilocybin Legalization

  • March 8, 2022
  • contact@ketaminemedia.com

Washington State citizens can rejoice to know their elected officials are making waves in the mental health world. Last month, a pair of Washington State lawmakers introduced new legislation that would legalize “supported psilocybin experiences” in those who are 21 years old and older. If it goes through, the Psilocybin Wellness and Opportunity Act will…

Ketamine vs. ECT Although ketamine is not yet FDA-approved for the treatment of mental health, there is growing evidence that the world of psychedelics is making big moves in the medical world. Recently, ketamine has gained the attention of many in its potential treatment of severe clinical depression. With discoveries come comparisons, and ketamine is…

Study Links Psychedelics to Reduced Risk of Heart Disease

  • March 1, 2022
  • contact@ketaminemedia.com

A recent study published in Scientific Reports suggests that individuals who have used traditional psychedelics may be at lower risk for cardiac disease. While these new findings are exciting, they serve to highlight the need for further research into the potential medical uses of psychedelics like psilocybin, LSD, and ketamine. “In our previous research, we…

Call Us
Consultation